Ropes & Gray represented Rallybio Corporation (Nasdaq: RLYB) in its agreement to acquire Candid Therapeutics, Inc., through a merger transaction. Upon completion of the Merger, the combined company expects to operate under the name Candid Therapeutics and trade on Nasdaq under the ticker symbol "CDRX". The agreement was announced on March 2.
Rallybio is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases.
Candid is a global clinical-stage biotechnology company advancing a leading portfolio of T-cell engager ("TCE") therapeutics for autoimmune diseases.
The team was led by M&A partner Zach Blume and included executive compensation & employee benefits partner Renata Ferrari, tax partner Pamela Glazier, and health care partner Eve Brunts.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.